

# New Venturetec

## NET ASSET VALUE - October 31, 2018

Shares issued private	4'500'000	Price: USD 23.83	USD 107'250'000
Shares issued IPO	500'000	Price: CHF 33.00 (ex.rate 1.47)	USD 11'250'000
	<b>5,000,000</b>		<b>USD 118'500'000</b>

<b>Total paid in capital</b>	<b>USD</b>	<b>118'500'000.00</b>
------------------------------	------------	-----------------------

Realized gain* (since inception to date)	USD	75'269'925.93
Realized loss* (since inception to date)	USD	109'585'211.82

\*inclusive reinvestments

### Investment appreciation of current portfolio companies

Unrealized gain	USD	18'859'350.14
Unrealized loss	USD	0.00
<b>Total appreciation</b>	USD	<b>18'859'350.14</b>

### NAV

Cost of investments	USD	28'475'733.64
Appreciation of investments	USD	18'859'350.14
Estimated value of investments	USD	<b>47'335'083.78</b>
Convertible Notes	USD	-13'310'808.57
Loan	USD	-7'665'458.41
Bank Loan	USD	0.00
Accrued expenses	USD	0.00
Accounts receivables	USD	0.00
Cash at bank	USD	872'834.45
<b>Estimated value</b>	USD	<b>27'231'651.25</b>
<b>NAV per share USD</b>		<b>5.45</b>
<b>NAV per share CHF</b>		<b>5.48</b>

Exchange rate USD/CHF	1.0063
<b>Closing Market Price October 31, 2018</b>	<b>CHF 4.60</b>

**New Venturetec**  
**NAV - October 31, 2018**

<b>INDUSTRY/ COMPANY</b>	<b>AMOUNT USD</b>	<b>% CAPITAL</b>	<b>SECURITIES</b>	<b>PRICE COST</b>	<b>PRICE REPORTED</b>	<b>UNREALIZED GAIN (LOSS)</b>	<b>TOTAL EST. VALUE</b>	<b>% NAV</b>
1. Osiris Therapeutics, Inc.	23'780'932.93	83.5	4'103'301 Common Shares	5.80	9.78	16'349'350.85	40'130'283.78	83.3
2. Myriad Genetics	4'694'800.71	16.5	160'000 Shares	29.34	45.03	2'509'999.29	7'204'800.00	14.9
<b>TOTAL</b>	<b>28'475'733.64</b>	<b>100.0</b>				<b>18'859'350.14</b>	<b>47'335'083.78</b>	<b>98.2</b>